On March 3, 2026, Mesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President of the Company, effective on or about April 13, 2026 (the Transition Date). Mr. Owens also resigned as a member of the Company?s board of directors, effective as of March 20, 2026. Mr. Owens' resignation from the Board is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
In connection with Mr. Owens? departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company?s new President, effective on or about April 13, 2026 (the Effective Date). The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date.
Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation.
From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company?s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005.
Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.
